5 completed. 5 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 2 | 1 | Completed 1 |
Follow plerixafor: new trials by email Literature Review of plerixafor trials Research Report on plerixafor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Plerixafor, G-CSF - Myelokathexis, Infections | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2014-10-14 | 2026-06-26 |
| Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation Granulocyte-colony stimulating factor (G-CSF), Plerixafor, Placebo - Non-Hodgkin's Lymphoma | Phase 3 | Completed | Sanofi | 100 | 2013-04-01 | 2014-12-09 |
| Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma bortezomib (Velcade), cyclophosphamide, G-CSF - Multiple Myeloma | Phase 3 | Completed | Weill Medical College of Cornell University | 47 | 2011-03-01 | 2019-12-27 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo - Multiple Myeloma | Phase 3 | Completed | Genzyme, a Sanofi Company | 302 | 2005-01-01 | 2014-03-13 |
| Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo - Lymphoma, Non-Hodgkin | Phase 3 | Completed | Genzyme, a Sanofi Company | 298 | 2005-01-01 | 2014-03-13 |
Lymphoma, Non-Hodgkin (2) · Multiple Myeloma (2) · Agammaglobulinemia (1) · Immunologic Deficiency Syndromes (1) · Infections (1) · Neutropenia (1) · Warts (1)
Genzyme, a Sanofi Company (2) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Sanofi (1) · Weill Medical College of Cornell University (1)
United States (4) · Canada (2) · China (1) · Germany (1)
David H McDermott, M.D. (1) · Ruben Niesvizky, MD (1)
PMID 19363221, PMID 19720922, PMID 37561579, PMID 42606118
2005 (1)